ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

LUCD Lucid Diagnostics Inc

1.5125
-0.0775 (-4.87%)
29 Mar 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Lucid Diagnostics Inc NASDAQ:LUCD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0775 -4.87% 1.5125 1.48 1.70 1.60 1.50 1.58 701,702 04:00:01

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

09/10/2024 1:01pm

PR Newswire (US)


Lucid Diagnostics (NASDAQ:LUCD)
Historical Stock Chart


From Sep 2024 to Mar 2025

Click Here for more Lucid Diagnostics Charts.

NEW YORK, Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the 2024 Maxim Healthcare Virtual Summit.

Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)

Event Details:

  • Date: Tuesday, October 15, 2024
  • Time: 11:30 AM Eastern Time
  • Format: Fireside Chat with Dennis McGrath, Lucid's Chief Financial Officer
  • Venue: Virtual

For more information about the 2024 Maxim Healthcare Virtual Summit and to attend Lucid's fireside chat, please visit https://m-vest.com/events/healthcare-10152024. 

A recording of the fireside chat will be made available on the investor relations section of the Company's website at ir.luciddx.com following the conclusion of the conference.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-the-2024-maxim-healthcare-virtual-summit-302271379.html

SOURCE Lucid Diagnostics

Copyright 2024 PR Newswire

1 Year Lucid Diagnostics Chart

1 Year Lucid Diagnostics Chart

1 Month Lucid Diagnostics Chart

1 Month Lucid Diagnostics Chart